Cite

HARVARD Citation

    Revenko, A. et al. (2022). Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer. Journal for immunotherapy of cancer. 10 (4), p. . [Online]. 
  
Back to record